Back to Awarded Treatment Trials
Awarded Trial: 06TGF-966
Grant ID
06TGF-966
Illness
Schizophrenia
Primary Drug/Intervention
Varenicline
Primary Dosage
1 mg
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Hong
Sample Size
60
Duration of Study Period for Each Subject
9 weeks
Outcome Measurements
BPRS, Biomakers, SDS, SANS, Quality of Life, MCCB
Results
Sixty-nine (69) patients with schizophrenia, both smokers and nonsmokers, were randomized to varenicline or placebo as adjunct medication for 8 weeks. Varenicline has activity on the nicotine acetylcholine receptors. Those on varenicline had significantly reduced P-50 sensory gating and startle reactivity and improved executive function. There was also a trend toward improved symptoms but no improvement in other cognitive functions.
Publication
Hong EL, Thaker GK, McMahon RP. Effects of Moderate-Dose Treatment with Varenicline on Neurobiological and Cognitive Biomarkers in Smokers and Nonsmokers With Schizophrenia or Schizoaffective Disorder. Arch Gen Psychiatry Dec. 2011; 68(12):1195-1206.
Link
http://www.ncbi.nlm.nih.gov/pubmed/21810630
PI Name
L Hong
Degree
MD
Center
Maryland Psychiatric Research Centrer
Institution
University of Maryland School of Medicine
Address
PO Box 21247
City or Town
Baltimore
State or Province
MD
Zip or Postal Code
21228
Country
USA
Email Address
ehong@mprc.umaryland.edu